A 24-year-old male with a history of relapsed B-ALL received CD19 CAR-T therapy (tisagenlecleucel), which was complicated by grade 3 CRS and grade 2 immune effector cell associated neurotoxicity syndrome (ICANS) with temporally associated atrial fibrillation. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.